Related Experiment Videos
Disseminated intravascular coagulation. Approach to treatment
1Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania.
Insights
Disseminated intravascular coagulation (DIC) is a critical condition involving systemic thrombin generation. Treatment focuses on the underlying cause, with heparin used for severe bleeding or thrombosis, especially in chronic cases.
Area of Science:
- Hematology
- Pathophysiology
- Critical Care Medicine
Background:
- Disseminated intravascular coagulation (DIC) is a life-threatening syndrome characterized by systemic thrombin generation.
- DIC results from pathological activation of coagulation pathways, often triggered by sepsis, malignancy, or trauma.
- Diagnosis relies on specific laboratory abnormalities, including prothrombin time, platelet count, fibrinogen, and fibrin degradation products.
Purpose of the Study:
- To outline the pathophysiology, diagnosis, and management strategies for disseminated intravascular coagulation (DIC).
- To differentiate clinical manifestations and treatment approaches for acute versus chronic DIC.
- To provide guidance on therapeutic interventions, including anticoagulation and supportive care.
Main Methods:
- Review of existing literature on DIC pathophysiology and clinical presentation.
- Analysis of diagnostic criteria based on laboratory values.
- Evaluation of treatment protocols for acute and chronic DIC, including heparin therapy and supportive measures.
Main Results:
- The most common presentation of DIC is bleeding, though thrombosis occurs in chronic forms, particularly with malignancy.
- Acute DIC management prioritizes treating the underlying condition and supportive care; heparin is indicated for severe hemorrhage or thrombosis.
- Chronic DIC, especially with thrombosis, is managed with heparin; warfarin is ineffective, and long-term heparin may be necessary.
Conclusions:
- Effective management of DIC requires prompt diagnosis and tailored treatment based on the underlying cause and clinical presentation.
- Heparin anticoagulation is a key therapeutic option for severe or persistent DIC, particularly in chronic cases.
- Addressing the primary disease and providing supportive care are crucial for improving outcomes in patients with DIC.
Abstract:
Disseminated intravascular coagulation (DIC) is a syndrome caused by the systemic generation of thrombin. Most cases are due to pathological activation of the intrinsic coagulation systems (e.g. in sepsis), and/or the extrinsic system (e.g. in malignancy and head trauma). Diagnosis is made by finding abnormalities in at least 3 of 4 laboratory values, namely prothrombin time, platelet count, fibrinogen and fibrinogen/fibrin degradation products. The most common clinical manifestation of DIC is bleeding, with thrombosis in less than 10% of acute cases but more frequently encountered in chronic DIC associated with malignancy. Acute DIC must first be treated by specific therapy of the underlying disease and general support measures. If serial clinical and laboratory monitoring improves, no further treatment is required. If severe or life-threatening haemorrhage occurs or a thrombotic event ensues, heparin anticoagulation followed by aggressive replacement with platelets, fresh plasma and possibly cryoprecipitate is indicated. Heparin doses should be 'therapeutic' (i.e. adequate to overcome the coagulant forces that may have produced a relative heparin-resistant state in the blood). Chronic DIC with haemorrhage, or more usually thrombosis, should also be treated with heparin; warfarin is ineffective. If DIC persists because, for example, a tumour does not regress, long term outpatient subcutaneous heparin therapy may be required.